Tirzepatide

Zepbound has a 5-day half-life, clearing 99% from your system in 4-5 weeks. Here’s what that means for weight maintenance, side effects, and restarting.

Zepbound reduces liver fat by 56% in NAFLD patients within 52 weeks, with fibrosis improvement in 40%. Here’s the mechanism, timeline, and candidacy.

Zepbound (tirzepatide) reduces liver fat by up to 44% in NAFLD patients through dual GLP-1/GIP action — mechanisms, timelines, and treatment

Zepbound calorie intake isn’t about starvation — optimal protein and fiber timing maximize fat loss while preserving lean mass. Here’s what works.

Mounjaro doesn’t directly treat social anxiety, but GLP-1 medications can influence mood through metabolic and neurological pathways affecting stress

Mounjaro reduces binge eating episodes by 60–70% in clinical observations through GLP-1 and GIP receptor agonism that normalizes hunger signaling.

Mounjaro’s GLP-1/GIP dual agonism shows measurable anti-aging biomarkers: reduced systemic inflammation, improved insulin sensitivity, enhanced autophagy.

Mounjaro isn’t FDA-approved for smoking cessation, but emerging evidence suggests GLP-1 receptor agonists may reduce nicotine cravings through dopamine

Mounjaro (tirzepatide) hasn’t shown causation with Parkinson’s disease, but drug interactions and metabolic effects require careful monitoring in